Molecular markers for breast cancer diagnosis, prognosis and targeted therapy

Journal of Surgical Oncology

Volumn 111, Issue 1, 2015, Pages 81-90

  Lang, Julie E ^a   Wecsler, Julie S ^a   Press, Michael F ^b   Tripathy, Debasish ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Biomarker; Breast cancer; Molecular marker; Personalized medicine; Precision medicine

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; MICRORNA; MOLECULAR MARKER; PLASMINOGEN ACTIVATOR INHIBITOR; PROGESTERONE RECEPTOR; TUMOR MARKER; UROKINASE; ANTINEOPLASTIC AGENT;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CIRCULATING TUMOR CELL; EPITHELIAL MESENCHYMAL TRANSITION; GENOTYPE; HUMAN; IMMUNOHISTOCHEMISTRY; MOLECULARLY TARGETED THERAPY; NEXT GENERATION SEQUENCING; NONHUMAN; PATIENT CARE; REVIEW; BREAST NEOPLASMS; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; PROGNOSIS;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MOLECULAR TARGETED THERAPY; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84920141745     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23732     Document Type: Review

References (105)

1. McShane LM, Hayes DF: Publication of tumor marker research results: The necessity for complete and transparent reporting. J Clin Oncol 2012;30:4223-4232.
2. Harris L, Fritsche H, Mennel R, et al.: American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007;25: 5287-5312.
3. Meric-Bernstam F, Farhangfar C, Mendelsohn J, et al. Building a personalized medicine infrastructure at a major cancer center. J Clin Oncol 2013;31:1849-1857.
4. Fisher B, Costantino J, Redmond C, et al.: A randomized clinical trial evaluating tamoxifen in the treatment of patients with nodenegative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 1989;320:479-484.
5. Cuzick J, Sestak I, Baum M, et al.: Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10- year analysis of the ATAC trial. Lancet Oncol 2010;11:1135-1141.
6. Harvey JM, Clark GM, Osborne CK, et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999;17:1474-1481.
7. Mohsin SK, Weiss H, Havighurst T, et al.: Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: A validation study. Modern pathology: An official journal of the United States and Canadian Academy of Pathology. Inc 2004;17: 1545-1554.
8. Bartlett JM, Brookes CL, Robson T, et al.: Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: A prospectively powered pathology study in the tamoxifen and exemestane adjuvant multinational trial. J Clin Oncol 2011;29:1531-1538.
9. van de Water W, Fontein DB, van Nes JG, et al.: Influence of semiquantitative oestrogen receptor expression on adjuvant endocrine therapy efficacy in ductal and lobular breast cancer - a TEAM study analysis. Eur J Cancer 2013;49:297-304.
10. Hammond ME, Hayes DF, Dowsett M, et al.: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010;28: 2784-2795.
11. Yi M, Huo L, Koenig KB, et al.: Which threshold for ER positivity? A retrospective study based on 9639 patients. Ann Oncol 2014.
12. Slamon DJ, Leyland-Jones B, Shak S, et al.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344: 783-792.
13. Wolff AC, Hammond ME, Hicks DG, et al.: Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 2013;31:3997-4013.
14. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al.: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Eng J Med 2005;353:1659-1672.
15. Romond EH, Perez EA, Bryant J, et al.: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Eng J Med 2005;353:1673-1684.
16. Slamon D, Eiermann W, Robert N, et al.: Adjuvant trastuzumab in HER2-positive breast cancer. N Eng J Med 2011;365:1273-1283.
17. Goldhirsch A, Gelber RD, Piccart-Gebhart MJ, et al.: 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): An open-label, randomised controlled trial. Lancet 2013;382:1021-1028.
18. Bose R, Kavuri SM, Searleman AC, et al.: Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov 2013;3:224-237.
19. Press MF, Sauter G, Buyse M, et al.: Alteration of topoisomerase II-alpha gene in human breast cancer: Association with responsiveness to anthracycline-based chemotherapy. J Clin Oncol 2011;29:859-867.
20. Paik S, Shak S, Tang G, et al.: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Eng J Med 2004;351:2817-2826.
21. Albain KS, Barlow WE, Shak S, et al.: Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: A retrospective analysis of a randomised trial. Lancet Oncol 2010;11:55-65.
22. Baehner FL, Achacoso N, Maddala T, et al.: Human epidermal growth factor receptor 2 assessment in a case-control study: Comparison of fluorescence in situ hybridization and quantitative reverse transcription polymerase chain reaction performed by central laboratories. J Clin Oncol 2010;28:4300-4306.
23. Cuzick J, Dowsett M, Pineda S, et al.: Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. J Clin Oncol 2011;29:4273-4278.
24. Senkus E, Kyriakides S, Penault-Llorca F, et al.: Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013;24:vi7-23.
25. Gion M, Mione R, Leon AE, et al.: CA27.29: A valuable marker for breast cancer management. A confirmatory multicentric study on 603 cases. Eur J Cancer 2001;37:355-363.
26. Bjohle J, Bergqvist J, Gronowitz JS, et al.: Serum thymidine kinase activity compared with CA 15 3 in locally advanced and metastatic breast cancer within a randomized trial. Breast Cancer Res Treat 2013;139:751-758.
27. Dowsett M, Nielsen TO, A'Hern R, et al.: Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst 2011;103:1656-1664.
28. Dowsett M, Smith IE, Ebbs SR, et al.: Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. Clin Cancer Res 2005;11:951s- 958s.
29. Ellis MJ, Tao Y, Luo J, et al.: Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst 2008;100: 1380-1388.
30. Ellis MJ, Suman VJ, Hoog J, et al.: Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptorrich stage 2 to 3 breast cancer: Clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype-ACOSOG Z1031. J Clin Oncol 2011;29:2342-2349.
31. Denkert C, Loibl S, Muller BM, et al.: Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: A translational investigation in the neoadjuvant GeparTrio trial. Ann Oncol 2013;24:2786-2793.
32. Harbeck N, Schmitt M, Meisner C, et al.: Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients. Eur J Cancer 2013;49:1825-1835.
33. Sorlie T, Perou CM, Tibshirani R, et al.: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98:10869-10874.
34. van de Vijver MJ, He YD, van't Veer LJ, et al.: A gene-expression signature as a predictor of survival in breast cancer. N Eng J Med 2002;347:1999-2009.
35. Wang Y, Klijn JG, Zhang Y, et al.: Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005;365:671-679.
36. Nielsen TO, Parker JS, Leung S, et al.: A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin Cancer Res 2010;16:5222-5232.
37. Sgroi DC, Sestak I, Cuzick J, et al.: Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: A prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population. Lancet Oncol 2013;14:1067-1076.
38. Loi S, Haibe-Kains B, Desmedt C, et al.: Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol 2007;25:1239-1246.
39. Jerevall PL, Ma XJ, Li H, et al.: Prognostic utility of HOX B13: IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial. Br J Cancer 2011;104:1762-1769.
40. Ma XJ, Wang Z, Ryan PD, et al.: A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer cell 2004;5:607-616.
41. Drukker CA, van Tinteren H, Schmidt MK, et al.: Long-term impact of the 70-gene signature on breast cancer outcome. Breast Cancer Res Treat 2014;143:587-592.
42. Sgroi DC, Carney E, Zarrella E, et al.: Prediction of late disease recurrence and extended adjuvant letrozole benefit by the HOXB13/IL17BR biomarker. J Natl Cancer Inst 2013;105: 1036-1042.
43. Carter J, Elkin S, Barton J: Company Profile: N-of-One: realizing personalized medicine. Future Med 2011;8:311-315.
44. Perou CM: Molecular stratification of triple-negative breast cancers. Oncologist 2011;16:61-70.
45. Creighton CJ, Li X, Landis M, et al.: Residual breast cancers after conventional therapy display mesenchymal as well as tumorinitiating features. Proc Natl Acad Sci U S A 2009;106:13820-13825.
46. Fan C, Oh DS, Wessels L, et al.: Concordance among geneexpression- based predictors for breast cancer. N Eng J Med 2006; 355:560-569.
47. Carey LA, Dees EC, Sawyer L, et al.: The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007;13:2329-2334.
48. Liedtke C, Hatzis C, Symmans WF, et al.: Genomic grade index is associated with response to chemotherapy in patients with breast cancer. J Clin Oncol 2009;27:3185-3191.
49. Gluck S, Ross JS, Royce M, et al.: TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine +/- trastuzumab. Breast Cancer Res Treat 2012;132:781-791.
50. Hatzis C, Pusztai L, Valero V, et al.: A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA 2011;305:1873-1881.
51. Masuda H, Baggerly KA, Wang Y, et al.: Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin Cancer Res 2013;19:5533-5540.
52. Lehmann BD, Bauer JA, Chen X, et al.: Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011;121: 2750-2767.
53. Bertucci F, Ueno NT, Finetti P, et al.: Gene expression profiles of inflammatory breast cancer: correlation with response to neoadjuvant chemotherapy and metastasis-free survival. Ann Oncol 2014;25:358-365.
54. Esserman LJ, Berry DA, DeMichele A, et al.: Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL-CALGB 150007/150012, ACRIN 6657. J Clin Oncol 2012;30:3242-3249.
55. Symmans WF, Hatzis C, Sotiriou C, et al.: Genomic index of sensitivity to endocrine therapy for breast cancer. J Clin Oncol 2010;28:4111-4119.
56. Parker JS, Mullins M, Cheang MC, et al.: Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009;27: 1160-1167.
57. Azim HA Jr, Michiels S, Zagouri F, et al.: Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement. Ann Oncol 2013;24:647-654.
58. van 't Veer LJ, Dai H, van de Vijver MJ, et al.: Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415:530-536.
59. Province MA, Goetz MP, Brauch H, et al.: CYP2D6 Genotype and adjuvant tamoxifen: Meta-analysis of heterogeneous study populations. Clin Pharmacol Ther 2014;95:216-227.
60. Brauch H, Schroth W, Goetz MP, et al.: Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters. J Clin Oncol 2013;31:176-180.
61. Iorio MV, Croce CM: MicroRNAs in cancer: Small molecules with a huge impact. J Clin Oncol 2009;27:5848-5856.
62. de Rinaldis E, Gazinska P, Mera A, et al.: Integrated genomic analysis of triple-negative breast cancers reveals novel micro- RNAs associated with clinical and molecular phenotypes and sheds light on the pathways they control. BMC genomics 2013; 14:643.
63. Madhavan D, Zucknick M, Wallwiener M, et al.: Circulating miRNAs as surrogate markers for circulating tumor cells and prognostic markers in metastatic breast cancer. Clin Cancer Res 2012;18:5972-5982.
64. Al-Hajj M, Wicha MS, Benito-Hernandez A, et al.: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003;100:3983-3988.
65. Dontu G, Abdallah WM, Foley JM, et al.: In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev 2003;17:1253-1270.
66. Ginestier C, Hur MH, Charafe-Jauffret E, et al.: ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell stem cell 2007;1: 555-567.
67. Liu R, Wang X, Chen GY, et al.: The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Eng J Med 2007;356:217-226.
68. Kim MY, Oskarsson T, Acharyya S, et al.: Tumor self-seeding by circulating cancer cells. Cell 2009;139:1315-1326.
69. Roy S, Gascard P, Dumont N, et al.: Rare somatic cells from human breast tissue exhibit extensive lineage plasticity. Proc Natl Acad Sci U S A 2013;110:4598-4603.
70. Shats I, Gatza ML, Chang JT, et al.: Using a stem cell-based signature to guide therapeutic selection in cancer. Cancer Res 2011;71:1772-1780.
71. Kim J, Villadsen R, Sorlie T, et al.: Tumor initiating but differentiated luminal-like breast cancer cells are highly invasive in the absence of basal-like activity. Proc Natl Acad Sci U S A 2012;109:6124-6129.
72. Allard WJ, Matera J, Miller MC, et al.: Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 2004;10:6897-6904.
73. Cristofanilli M, Budd GT, Ellis MJ, et al.: Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Eng J Med 2004;351:781-791.
74. Lucci A, Hall CS, Lodhi AK, et al.: Circulating tumour cells in non-metastatic breast cancer: A prospective study. Lancet Oncol 2012;13:688-695.
75. Zhang L, Riethdorf S, WuG, et al.: Meta-analysis of the prognostic value of circulating tumor cells in breast cancer. Clin Cancer Res 2012;18:5701-5710.
76. Budd GT, Cristofanilli M, Ellis MJ, et al.: Circulating tumor cells versus imaging-predicting overall survival in metastatic breast cancer. Clin Cancer Res 2006;12:6403-6409.
77. Liu MC, Shields PG, Warren RD, et al.: Circulating tumor cells: A useful predictor of treatment efficacy in metastatic breast cancer. J Clin Oncol 2009;27:5153-5159.
78. Yu M, Bardia A, Wittner BS, et al.: Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 2013;339:580-584.
79. Braun S, Vogl FD, Naume B, et al.: A pooled analysis of bone marrow micrometastasis in breast cancer. N Eng J Med 2005;353: 793-802.
80. Dawson SJ, Tsui DW, Murtaza M, et al.: Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Eng J Med 2013;368:1199-1209.
81. Ring BZ, Seitz RS, Beck R, et al.: Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast cancer. J Clin Oncol 2006;24:3039-3047.
82. Bartlett JM, Bloom KJ, Piper T, et al.: Mammostrat as an immunohistochemical multigene assay for prediction of early relapse risk in the tamoxifen versus exemestane adjuvant multicenter trial pathology study. J Clin Oncol 2012;30:4477-4484.
83. Lea OA, Kvinnsland S, Thorsen T: Improved measurement of androgen receptors in human breast cancer. Cancer Res 1989;49: 7162-7167.
84. Vera-Badillo FE, Templeton AJ, de Gouveia P, et al.: Androgen receptor expression and outcomes in early breast cancer: A systematic review and meta-analysis. J Natl Cancer Inst 2014;106: djt319.
85. De Amicis F, Thirugnansampanthan J, Cui Y, et al.: Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells. Breast Cancer Res Treat 2010;121: 1-11.
86. Denkert C, Loibl S, Noske A, et al.: Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2010;28: 105-113.
87. Gonzalez-Angulo AM, Ferrer-Lozano J, Stemke-Hale K, et al.: PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer. Mol Cancer Ther 2011;10:1093-1101.
88. The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012;490:61-70.
89. Shah SP, Roth A, Goya R, et al.: The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 2012;486:395-399.
90. Curtis C, Shah SP, Chin SF, et al.: The genomic and transcriptomic architecture of 2, 000 breast tumours reveals novel subgroups. Nature 2012;486:346-352.
91. Jeselsohn R, Yelensky R, Buchwalter G, et al.: Emergence of constitutively active estrogen receptor-alpha mutations in pretreated advanced estrogen receptor positive breast cancer. Clin Cancer Res 2014;20:1757-1767.
92. Dave B, Migliaccio I, Gutierrez MC, et al.: Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers. J Clin Oncol 2011;29:166-173.
93. Frampton GM, Fichtenholtz A, Otto GA, et al.: Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nature Biotech 2013;31: 1023-1031.
94. Ross JS, Wang K, Sheehan CE, et al.: Relapsed classic E-cadherin (CDH1)-mutated invasive lobular breast cancer shows a high frequency of HER2 (ERBB2) gene mutations. Clin Cancer Res 2013;19:2668-2676.
95. Balko JM, Giltnane JM, Wang K, et al.: Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. Cancer Discov 2014;4:232-245.
96. Von Hoff DD, Stephenson JJ Jr, Rosen P, et al.: Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol 2010; 28:4877-4883.
97. Petrillo LA, Wolf DM, Kapoun AM, et al.: Xenografts faithfully recapitulate breast cancer-specific gene expression patterns of parent primary breast tumors. Breast Cancer Res Treat 2012;135: 913-922.
98. Zhang X, Claerhout S, Prat A, et al.:A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patientderived human breast cancer xenograft models. Cancer Res 2013; 73:4885-4897.
99. Zhang H, Cohen AL, Krishnakumar S, et al.: Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition. Breast Cancer Res 2014;16:R36.
100. Fruehauf JP: In vitro assay-assisted treatment selection for women with breast or ovarian cancer. Endocr Relat Cancer 2002;9: 171-182.
101. Samson DJ, Seidenfeld J, Ziegler K, et al. Chemotherapy sensitivity and resistance assays: A systematic review. J Clin Oncol 2004;22:3618-3630.
102. Schrag D, Garewal HS, Burstein HJ, et al.: American Society of Clinical Oncology Technology Assessment: Chemotherapy sensitivity and resistance assays. J Clin Oncol 2004;22:3631-3638.
103. Mi Z, Holmes FA, Hellerstedt B, et al.: Feasibility assessment of a chemoresponse assay to predict pathologic response in neoadjuvant chemotherapy for breast cancer patients. Anticancer Res 2008;28:1733-1740.
104. Sotiriou C, Wirapati P, Loi S, et al.: Gene expression profiling in breast cancer: Understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 2006;98: 262-272.
105. Chang HY, Nuyten DS, Sneddon JB, et al.: Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci U S A 2005;102:3738-3743.